Insomnia.
The launch of eszopiclone by Sepracor Inc in April 2005 in the US has marked the long-anticipated advent of a new generation of hypnotics that promise safer treatment for chronic insomnia. Over the coming years more compounds are expected to be launched, offering improved daytime well being and fewer side effects compared with their predecessors that were launched in the early 1990s. This article examines the factors that will drive the uptake of the new insomnia drugs by the public, describes potential barriers to adoption of these drugs and provides ideas for future treatment approaches that may offer better targeting and management of possible underlying conditions rather than merely controlling a symptom.
Holzinger
Erik
E
GroupH Ltd, London, UK. erik.holzinger@groupH.co.uk
D053961:Azabicyclo Compounds; D002986:Clinical Trials as Topic; D006801:Humans; D006993:Hypnotics and Sedatives / Q000737:chemistry / Q000191:economics / Q000627:therapeutic use; D015394:Molecular Structure; D010879:Piperazines / Q000737:chemistry / Q000627:therapeutic use*; D007319:Sleep Initiation and Maintenance Disorders / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology
D053961:Azabicyclo Compounds; D006993:Hypnotics and Sedatives; D010879:Piperazines; C515050:zopiclone